Datapoint: Gilead Snags Priority Review in ALL for Tecartus

Following positive Phase 2 trial data, the FDA granted Gilead Sciences’ Tecartus priority review for the treatment of adult acute lymphoblastic leukemia (ALL). The initial target date for the decision is Oct. 1. If approved, Tecartus will have to go up against Novartis’ CAR-T therapy, Kymriah, which was first approved for ALL in 2017. Under the medical benefit, Kymriah is covered for 88% of all insured lives.

SOURCE: MMIT Analytics, as of 6/9/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 19

Datapoint: Lilly Scores Diabetes, Obesity Nods for Mounjaro

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 18

Datapoint: CDPHP Selects New PBM

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 17

Datapoint: Oscar to Exit Two States

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today